189 related articles for article (PubMed ID: 9013384)
1. Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).
Schoepp DD; Salhoff CR; Fuson KS; Sacaan AI; Tizzano JP; Ornstein PL; May PC
J Neural Transm (Vienna); 1996; 103(8-9):905-16. PubMed ID: 9013384
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid.
Schoepp DD; Lodge D; Bleakman D; Leander JD; Tizzano JP; Wright RA; Palmer AJ; Salhoff CR; Ornstein PL
Neuropharmacology; 1995 Sep; 34(9):1159-68. PubMed ID: 8532186
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.
Alt A; Weiss B; Ogden AM; Li X; Gleason SD; Calligaro DO; Bleakman D; Witkin JM
Psychopharmacology (Berl); 2006 Apr; 185(2):240-7. PubMed ID: 16470401
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid.
Bleakman R; Schoepp DD; Ballyk B; Bufton H; Sharpe EF; Thomas K; Ornstein PL; Kamboj RK
Mol Pharmacol; 1996 Apr; 49(4):581-5. PubMed ID: 8609884
[TBL] [Abstract][Full Text] [Related]
5. Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons.
Liljequist S; Cebers G; Kalda A
Biochem Pharmacol; 1995 Nov; 50(11):1761-74. PubMed ID: 8615854
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution.
Ornstein PL; Arnold MB; Allen NK; Bleisch T; Borromeo PS; Lugar CW; Leander JD; Lodge D; Schoepp DD
J Med Chem; 1996 May; 39(11):2219-31. PubMed ID: 8667365
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
Weiss B; Alt A; Ogden AM; Gates M; Dieckman DK; Clemens-Smith A; Ho KH; Jarvie K; Rizkalla G; Wright RA; Calligaro DO; Schoepp D; Mattiuz EL; Stratford RE; Johnson B; Salhoff C; Katofiasc M; Phebus LA; Schenck K; Cohen M; Filla SA; Ornstein PL; Johnson KW; Bleakman D
J Pharmacol Exp Ther; 2006 Aug; 318(2):772-81. PubMed ID: 16690725
[TBL] [Abstract][Full Text] [Related]
8. Kainate receptor-mediated activation of the AP-1 transcription factor complex in cultured rat cerebellar granule cells.
Kovács AD; Cebers G; Liljequist S
Brain Res Bull; 2000 May; 52(2):127-33. PubMed ID: 10808083
[TBL] [Abstract][Full Text] [Related]
9. The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
Figueiredo TH; Qashu F; Apland JP; Aroniadou-Anderjaska V; Souza AP; Braga MF
J Pharmacol Exp Ther; 2011 Feb; 336(2):303-12. PubMed ID: 20962029
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
Apland JP; Aroniadou-Anderjaska V; Figueiredo TH; Green CE; Swezey R; Yang C; Qashu F; Braga MF
J Pharmacol Exp Ther; 2013 Jan; 344(1):133-40. PubMed ID: 23042954
[TBL] [Abstract][Full Text] [Related]
11. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
[TBL] [Abstract][Full Text] [Related]
12. Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischaemia.
Hicks CA; Ward MA; Swettenham JB; O'Neill MJ
Eur J Pharmacol; 1999 Sep; 381(2-3):113-9. PubMed ID: 10554878
[TBL] [Abstract][Full Text] [Related]
13. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons.
Benvenga MJ; Ornstein PL; Leander JD
J Pharmacol Exp Ther; 1995 Oct; 275(1):164-70. PubMed ID: 7562545
[TBL] [Abstract][Full Text] [Related]
14. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse.
Rogawski MA; Kurzman PS; Yamaguchi SI; Li H
Neuropharmacology; 2001; 40(1):28-35. PubMed ID: 11077068
[TBL] [Abstract][Full Text] [Related]
15. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus.
Bond A; Lodge D; Hicks CA; Ward MA; O'Neill MJ
Eur J Pharmacol; 1999 Sep; 380(2-3):91-9. PubMed ID: 10513567
[TBL] [Abstract][Full Text] [Related]
16. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia.
O'Neill MJ; Bond A; Ornstein PL; Ward MA; Hicks CA; Hoo K; Bleakman D; Lodge D
Neuropharmacology; 1998; 37(10-11):1211-22. PubMed ID: 9849659
[TBL] [Abstract][Full Text] [Related]
17. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury?
Prehn JH; Lippert K; Krieglstein J
Eur J Pharmacol; 1995 Jan; 292(2):179-89. PubMed ID: 7720791
[TBL] [Abstract][Full Text] [Related]
18. Kainate receptors are involved in synaptic plasticity.
Bortolotto ZA; Clarke VR; Delany CM; Parry MC; Smolders I; Vignes M; Ho KH; Miu P; Brinton BT; Fantaske R; Ogden A; Gates M; Ornstein PL; Lodge D; Bleakman D; Collingridge GL
Nature; 1999 Nov; 402(6759):297-301. PubMed ID: 10580501
[TBL] [Abstract][Full Text] [Related]
19. (S)-5-fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors.
Larm JA; Cheung NS; Beart PM
Eur J Pharmacol; 1996 Oct; 314(1-2):249-54. PubMed ID: 8957243
[TBL] [Abstract][Full Text] [Related]
20. Overactivation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate and N-methyl-D-aspartate but not kainate receptors inhibits phosphatidylcholine synthesis before excitotoxic neuronal death.
Gasull T; DeGregorio-Rocasolano N; Trullas R
J Neurochem; 2001 Apr; 77(1):13-22. PubMed ID: 11279257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
